Global Leading Market Research Publisher QYResearch announces the release of its latest report “Animal Experiment Mice – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”.
The accelerating complexity of modern drug discovery, gene therapy validation, and translational biomedical research has significantly increased the demand for standardized and genetically controlled laboratory models. However, pharmaceutical companies, academic institutions, and contract research organizations continue to face persistent challenges, including reproducibility gaps in preclinical trials, rising R&D costs, and stricter regulatory expectations for safety validation. The laboratory animal model mice market—particularly animal experiment mice—has therefore become a foundational pillar of biomedical research models, offering scalable, cost-effective, and genetically adaptable systems for disease modeling and therapeutic testing. These biotechnology research mice enable researchers to bridge the gap between in vitro experiments and human clinical outcomes, providing a critical solution for improving translational accuracy in life sciences innovation.
Following the rapid expansion of gene editing platforms such as CRISPR-Cas9 and advanced immunotherapy pipelines, demand for laboratory animal model mice has surged over the past six months, particularly in oncology and neuroscience research programs. Increased regulatory scrutiny from agencies such as the FDA and EMA has also reinforced the necessity of robust preclinical validation using standardized animal experiment mice, further accelerating global adoption.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5769601/animal-experiment-mice
The global market for laboratory animal model mice was estimated to be worth US$ million in 2025 and is projected to reach US$ million, expanding at a CAGR of % from 2026 to 2032. This growth trajectory reflects sustained investment in biotechnology research mice across pharmaceutical R&D pipelines, academic life sciences programs, and contract research organizations (CROs). Over the past six months, industry participants have increasingly shifted toward genetically engineered mouse models (GEMMs), particularly in immuno-oncology and neurodegenerative disease research, where disease-specific phenotypes are essential for predictive modeling.
A key structural driver is the rising integration of precision genetic engineering technologies into animal experiment mice production workflows. CRISPR-based knock-in and knock-out models, as well as inducible gene expression systems, are becoming standard tools in biomedical research models, significantly reducing development timelines for customized experimental animals. Additionally, cloud-based colony management systems and digital phenotype tracking platforms are improving reproducibility and data integrity across multi-site research networks.
The laboratory animal model mice market is segmented as below:
Key market participants include:
GemPharmatech Co., Ltd.
Shanghai Model Organisms Center, Inc.
Cyagen
Ozgene
Taconic
Czech Breeding Company
GemPharmatech
THE JACKSON LABORATORY
PolyGene
These organizations are increasingly competing on genetic engineering capabilities, strain diversity, and integrated service offerings rather than traditional breeding capacity alone. Over the past six months, strategic collaboration between biotech firms and pharmaceutical companies has intensified, particularly in co-developing disease-specific biotechnology research mice for oncology drug pipelines and rare disease modeling.
Segment by Type:
- Humanized Mice
- Transgenic Mice
- Others
Humanized mice have emerged as the fastest-growing segment within the laboratory animal model mice ecosystem due to their ability to mimic human immune responses, making them essential for immunotherapy and vaccine development. Transgenic mice remain widely used for gene function studies and hereditary disease modeling, while other models continue to serve niche experimental applications.
Segment by Application:
- Scientific Research Center
- University
- Company
- Others
Scientific research centers represent the largest consumption base of animal experiment mice, driven by large-scale government-funded biomedical programs and disease mechanism studies. Universities play a crucial role in early-stage discovery and academic innovation, while pharmaceutical and biotechnology companies increasingly rely on outsourced preclinical testing using standardized biomedical research models to accelerate drug development timelines.
A notable industry dynamic is the divergence between discovery-driven research environments and application-driven pharmaceutical pipelines. In academic institutions, laboratory animal model mice are primarily used for exploratory hypothesis testing and mechanistic studies. In contrast, pharmaceutical companies deploy highly standardized biotechnology research mice to ensure regulatory compliance and reproducibility across global clinical trials. This structural difference has led to differentiated procurement strategies, with academia favoring flexibility and pharma prioritizing validation consistency.
From a technological standpoint, the integration of gene-editing platforms with automated breeding and phenotyping systems has significantly enhanced the scalability of animal experiment mice production. Recent developments in 2025 include AI-assisted behavioral analysis systems capable of detecting subtle phenotypic changes in neurological disease models, improving early-stage drug screening accuracy. These advancements are particularly relevant in neurodegenerative disease research, where early biomarker detection is critical.
Despite strong growth momentum, the laboratory animal model mice market faces several challenges, including ethical concerns related to animal welfare, rising costs of genetically engineered strain development, and regulatory variability across regions. The 3Rs principle (Replacement, Reduction, Refinement) continues to shape policy frameworks in Europe and North America, encouraging the development of alternative models while still sustaining demand for high-precision biotechnology research mice.
An emerging trend is the increasing outsourcing of mouse model development to specialized service providers. Pharmaceutical companies are reducing in-house breeding operations and instead relying on CROs for customized animal experiment mice solutions, enabling cost efficiency and faster project turnaround. This outsourcing model is expected to become more dominant over the forecast period, particularly in mid-sized biotech firms.
In conclusion, the global laboratory animal model mice market is positioned for sustained expansion as biomedical innovation accelerates across oncology, immunology, and neuroscience. The convergence of gene editing technologies, digital research infrastructure, and standardized biomedical research models is reshaping the preclinical research landscape. As demand for reproducible and human-relevant data intensifies, biotechnology research mice will remain a critical enabler of next-generation therapeutic development.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
